Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 5/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL28467818 | 1.00 | MEN1 (0.44) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL1196246 | 1.00 | MEN1 (0.44) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL1820143 | 0.91 | MEN1 (0.52) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL162687 | 0.91 | MEN1 (0.52) | MEN1KMT2ABLMARG1SLC1A2 | |
| Glycine SCHEMBL3091838 | 0.87 | SLC1A2 (0.48) | MEN1KMT2ABLMARG1SLC1A2 | |
| Glycine SCHEMBL3390130 | 0.87 | SLC1A2 (0.48) | MEN1KMT2ABLMARG1SLC1A2 | |
| Proline SCHEMBL418934 | 0.86 | NOS2 (0.45) | MEN1KMT2ABLMNOS2NOS3 | |
| Proline SCHEMBL3097543 | 0.86 | NOS2 (0.45) | MEN1KMT2ABLMNOS2NOS3 | |
| Proline SCHEMBL1675389 | 0.86 | NOS2 (0.45) | MEN1KMT2ABLMNOS2NOS3 | |
| Proline SCHEMBL1429909 | 0.86 | NOS2 (0.45) | MEN1KMT2ABLMNOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041792-A1 | TOPICAL COMPOSITIONS AND USES THEREOF | TRUETIVA, Inc. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230240992-A9 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY | RELIEVE THERAPEUTICS PTE. LTD. (SG) | 2023-08-03 | — | — | US | disclosed |
| US-20220160689-A1 | COMPOSITIONS AND METHODS FOR PAIN RELIEF AND NUMBING | Ziropa, Inc. (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3694489-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | Illustris Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019075263-A2 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | ILLUSTRIS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190105261-A1 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY | ILLUSTRIS PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-7560430-B2 | To stimulate the endogenous production of Elastin or appear to enhance the elasticity of the skin | HUMAN MATRIX SCIENCES, LLC (US) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041792-A1 | TOPICAL COMPOSITIONS AND USES THEREOF | COL14A1, COL2A1, COL1A1 | MEN1 4456/4885KMT2A 4199/4885BLM 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.